Last reviewed · How we verify
autologous cord blood stem cell
autologous cord blood stem cell is a Small molecule drug developed by Assistance Publique Hopitaux De Marseille. It is currently in Phase 1 development.
At a glance
| Generic name | autologous cord blood stem cell |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly (PHASE2)
- Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease (PHASE1)
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (PHASE2)
- Extracellular Vesicles for the Treatment of Syringomyelia (PHASE1)
- Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors (EARLY_PHASE1)
- Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome (PHASE2)
- Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD (PHASE1)
- Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- autologous cord blood stem cell CI brief — competitive landscape report
- autologous cord blood stem cell updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI
Frequently asked questions about autologous cord blood stem cell
What is autologous cord blood stem cell?
autologous cord blood stem cell is a Small molecule drug developed by Assistance Publique Hopitaux De Marseille.
Who makes autologous cord blood stem cell?
autologous cord blood stem cell is developed by Assistance Publique Hopitaux De Marseille (see full Assistance Publique Hopitaux De Marseille pipeline at /company/assistance-publique-hopitaux-de-marseille).
What development phase is autologous cord blood stem cell in?
autologous cord blood stem cell is in Phase 1.